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Abstract
Lack of efficacy and drug-related adverse effects are important reasons for the discontinuation of treat-
ment in patients with rheumatic diseases. The development of new biologic therapies seeks to address
these problems by specifically targeting the pathogenic mechanisms of disease. Most current biologics
are proteins (particularly antibodies and enzymes) administered parenterally. It is important to optimize
properties such as serum half-life, immunogenicity and solubility. Companies have thus begun to modify
the drugs by conjugate chemistry, binding inert molecules such as polyethylene glycol (PEG) to biologic
molecules to improve their pharmacodynamic properties. The use of PEG to alter these properties has to
be weighed against the negative aspects of PEGylation, such as decreased activity and heterogeneity.
This review focuses on the currently available PEGylated drugs used in rheumatological diseases, their
efficacy, drawbacks and the current clinical trial evidence supporting their use.
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Introduction
PEGylation refers to the covalent binding of polyethylene
glycol (PEG) molecules to proteins. The large PEG groups
alter the physical properties of the molecule, such as
solubility, thermal stability and immunogenicity. These
changes may be utilized to render biologically active pro-
teins suitable for therapeutic use through modification of
their pharmacokinetic and pharmacodynamic properties,
such as prolongation of half-life in vivo or inhibition of
degradation by proteases.
In rheumatology, PEGylation is highly relevant to the
new generation of biologic drugs, most of which are
proteins. Examples include antibodies such as anti-
TNF drugs, used in inflammatory arthritis, and enzymes
such as uricase, used in gout. This review describes the
challenges that have been encountered in developing
these PEGylated biologic agents and the evidence
regarding their efficacy in treating rheumatological
diseases.
Advantages and disadvantages of PEGylation
PEG molecules bind to amino acids in the target protein
by means of chemical linkers [1]. The number, sites of
attachment and molecular weights of the PEG molecules
can be varied in order to optimize the biologic properties
of the PEGylated product, notably half-life and immuno-
genicity. PEG itself has low immunogenicity, low antigeni-
city and low toxicity [1, 2]. PEGylation prolongs the in vivo
half-life of protein-based drugs by several mechanisms
[36]. The large PEG groups increase the hydrodynamic
volume of the molecule such that it is less likely to be
excreted by the kidney due to low levels of permeability
through the renal basement membrane [2, 7]. The hydro-
dynamic volume of the PEGylated molecule increases
sharply with the molecular weight of the PEG attached.
A 10 kDa PEG has a similar hydrodynamic volume to a
protein of 65.4 kDa, but a 40 kDa PEG has a hydro-
dynamic volume approaching that of a protein of
670 kDa [8]. PEG groups protect the protein from prote-
olysis and from the immune system, avoiding formation
of immune complexes and degradation [2, 9]. Repulsion
between PEG groups on separate molecules reduces
aggregation and improves thermal stability [8, 10]. PEG
dissolves at high concentrations in both water and organic
solvents, so PEGylation improves the solubility of proteins
in both [8, 10]. PEG also has very low toxicity, having been
shown to be harmless to animals at concentrations
as high as 16 g/kg (1000-fold higher than the normal thera-
peutic dose of proteinPEG conjugates in humans) [7].
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One of the main problems with PEGylation is the het-
erogeneity of the products produced. Since most proteins
contain a number of possible attachment sites for PEG
molecules, the product of a chemical reaction between
protein and PEG is typically a mixture of isomers contain-
ing different numbers of PEG groups (monoPEGylated,
diPEGylated, etc.) or in which PEG has been attached
at different places. These isomers may vary in biologic
activity so it is difficult to control or predict the properties
of the mixture. A number of techniques can be used to
address this problem. Some PEGylation methods target
specific amino acids such as histidine, cysteine or disul-
phide bridges, limiting the potential sites of PEGylation
on any protein. Restriction of the PEG:protein ratio used
in the reaction and variation of temperature conditions
can drive the reaction in favour of producing only
monoPEGylated products. MonoPEGylated products
can be separated from those containing larger numbers
of PEG by size-exclusion chromatography, though it is
very difficult to separate different monoPEGylated iso-
mers from each other. However, it is possible that using
a mixture of such monoPEGylated isomers therapeutically
could have advantages. For example, antibodies against
one isomer might not bind to others, thus reducing their
effect on the efficacy of the drug as a whole. In fact,
antibodies to PEG itself have been estimated to occur in
825% of the population [11, 12], probably due to the
presence of PEG in normal household items such as
hand creams.
Another issue with the efficacy of PEGylated drugs is
that the PEG groups may hamper access of the substrate
to the active site of the molecule, thus reducing the bind-
ing affinity and biologic activity of the molecule. Affinity
can also be reduced where the binding of PEG causes
conformational changes and disruption of the pattern of
electrostatic charges on the surface of the molecule [9].
Depending on the method of PEGylation and the weight of
bound PEG, activity retained in the PEGylated product
may vary widely, from 7% to 98% [1]. One study
showed that binding of 40 kDa of PEG to IFNa-2 a
(19 kDa) reduced its activity to 7% [2] of the native protein.
Conversely, others have noted that use of bifunctional
PEG (i.e. able to bind two target molecules creating
dimers) can give highly active conjugates with little vari-
ability in size [1]. The position at which the PEG is at-
tached can also be critical in determining the effects on
activity. For example, filgrastim is recombinant human
granulocyte colony-stimulating factor used to treat neu-
tropenia. UnPEGylated filgrastim has a short serum half-
life, necessitating daily injections. Random PEGylation
can be used to increase the half-life, but at the cost of
reduced activity. However, site-specific PEGylation of
filgrastim at the N-terminal amino group enabled better
retention of biologic activity; this monoPEGylated variant
is marketed as Neulasta [13]. More recently a new variant
of PEGylated filgrastim, in which a single PEG is added
enzymatically at glutamine 135, was shown to have 50%
better activity in a bioassay than Neulasta [14] (although it
was still not as active as unPEGylated filgrastim).
In some PEGdrug conjugates, the PEG is released in
vivo due to the use of a linker, which is either hydrolytically
unstable or susceptible to enzymatic cleavage. Loss of
the PEG might lead to toxicity or a shortened half-life
and this problem led to abandonment of one drug
(Pegamotecan, a PEGylated camptothecin) due to a lack
of efficacy [2]. On the other hand, gradual loss of PEG can
also be seen as an advantage if the PEGylated form is
seen as a pro-drug of reduced activity from which the
fully active form of the protein is released by hydrolysis
of the linker and loss of PEG. PEG-intron (PEGylated
IFNa-2 b) is an example of such a pro-drug. PEGylation
at His-34 is unstable because of the susceptibility of the
linker at that site to hydrolysis [2, 15].
In one study using PEGylated TNF-binding protein, ad-
ministration of the conjugate (but not free PEG or free
protein) induced the unexpected side effect of vacuolation
of the renal cortical tubular epithelium after 3 months [8].
The interaction between PEG and protein can have sig-
nificant effects on viscosity. Thus Kerwin et al. [16]
showed that a mixture of PEG with soluble TNF receptor
1 (sTNF-R1) had a viscosity up to five times higher than
that of PEG alone or sTNF-R1 alone, depending on
the pH. Viscosity was highest at pH> 5.2. A highly vis-
cous product would not be ideal for therapeutics.
Having described the potential advantages and disadvan-
tages of PEGylation, we will now outline the ways
in which both have affected the development of
PEGylated agents for two rheumatological conditions:
gout and RA.
PEGylated uricase in gout
Uricase (also referred to as urate oxidase) is an enzyme,
thought to have been lost in evolution in humans, that
metabolizes uric acid to allantoin [46]. Uricase has
been investigated as a treatment for patients who do
not respond fully to xanthine oxidase inhibitors such as
allopurinol.
Initially uricase purified from Aspergillus flavus and pigs
suffered the problems of a short half-life and the great
possibility of an immunogenic reaction, curtailing its pro-
gression into clinical trials [6]. More recently, clinical trials
have been carried out on PEGylated uricase [46, 17, 18].
An initial pre-clinical study [4] assessed intra-peritoneal
administration of recombinant chimeric pigbaboon
uricase to uricase double-negative homozygote mice.
Unmodified recombinant uricase was ineffective. It dis-
appeared from the circulation 424 h after injection and
reduction of serum urate from 10.2 mg/dl at baseline to
6.3 mg/dl at 4 h was transient, returning to normal in 24 h.
The transient nature of this effect could not be solved by
repeated injections of unmodified uricase because anti-
uricase antibodies appeared after the second injection
and increased after subsequent injections. The results
with PEGylated enzyme were much better. Repeated in-
jections (up to 10) did not result in any serum anti-uricase
antibodies, and when the injections were given at 5-day
intervals the presence of serum uricase and reductions in
both serum urate and urinary uric acid were maintained
between injections [4]. Use of a recombinant uricase
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combining sequence features of the pig and baboon en-
zymes was advantageous. Baboon uricase is less active
than porcine uricase but more similar to the human
enzyme (reducing immunogenicity). This PEGylated
pigbaboon uricase, later designated pegloticase, was
then taken forward into clinical trials.
Phase 1 trials of single doses of s.c. (n= 13) [17] and i.v.
(n= 24) [6] PEGylated uricase were carried out in patients
with hyperuricaemia and clinical gout who did not respond
to standard oral urate-lowering agents. Both routes of ad-
ministration produced rapid decreases in plasma uric
acid, with the effect being maintained for 21 days in 11/
13 patients given s.c. drug and 24/24 given i.v. drug.
However, the latter route gave lower uric acid and
higher plasma uricase levels, whereas localized pain at
the injection site and poor absorption were problems
with s.c. injection. The PEGylated uricase was immuno-
genic, with anti-PEG uricase or anti-PEG antibodies
developing in 5/13 patients given s.c. drug and 9/24
patients given i.v. drug. Although development of these
antibodies caused more rapid clearance of PEGylated
uricase, it did not cause severe allergic reactions and
the i.v. drug was well tolerated. It was taken forward
into a longer (1214 week) phase II trial [5] in which 41 pa-
tients with refractory hyperuricaemia were randomized to
one of four doses: 4 mg every 2 weeks, 8 mg every
2 weeks, 8 mg every 4 weeks or 12 mg every 4 weeks.
Although there was evidence of efficacy, it is striking
that 15 of the 41 patients withdrew from the study, with
infusion reactions being the reason in 12 of these. The
mean urate level remained <6 mg/dl in all four treatment
groups and the primary end point (plasma urate <6 mg/dl
for at least 80% of the study period) was achieved by
5088% of the patients in different groups. The best re-
sponse was in the 8 mg every 2 weeks group, where 88%
achieved this end point. On the other hand, 88% of all
patients reported at least one flare of gout during
the study period and 76% of patients developed anti-
pegloticase antibodies. The presence of these antibodies
reduced efficacy and increased clearance rates while anti-
body-negative patients showed a 100% response rate [5].
The authors reported that anti-pegloticase-positive pa-
tients who were treated every 2 weeks were more likely
to respond than those who got the drug every 4 weeks
(80 vs. 33%) [5]. Overall this trial established 8 mg/infusion
as the likely optimal dose, with a possible benefit of
fortnightly rather than monthly administration, and the
efficacy of this approach was tested in two replicate
double-blind, randomized, placebo-controlled studies
reported in 2011 [18].
In these replicate trials all subjects received fortnightly
infusions that were either 8 mg pegloticase every infusion,
8 mg pegloticase alternating with placebo (i.e. the active
drug was being given monthly) or placebo every infusion.
Responders were defined as having plasma uric acid
<6 mg/dl for at least 80% of the time in months 3 and 6.
Of the 225 patients enrolled, all had a decrease in plasma
uric acid after the first pegloticase infusion, but this re-
sponse was not maintained in all subjects such that the
overall response rate was 42% in the fortnightly pegloti-
case group, 35% in the monthly pegloticase group and 0
in the placebo group. There was a reduction in flares of
gout in the fortnightly pegloticase group compared with
placebo between months 4 and 6, but not at earlier time
points. However, flares of gout did occur in 80% of sub-
jects across all three groups. Although patients were given
prophylactic hydrocortisone, fexofenadine and acet-
aminophen, infusion reactions remained more common
in the fortnightly (26%) and monthly pegloticase (42%)
groups than the placebo group (5%). Withdrawals due
to infusion reactions were less frequent, however, than
in the previous open study (10% for the fortnightly group
and 13% for monthly) [5]. Although seven subjects died,
this was not thought to be related to the drug. Three
deaths occurred in the placebo group and the patients
who died had co-morbidities such as cardiovascular
disease.
As in the previous studies, pegloticase proved to be
immunogenic, with 134/150 subjects who received the
drug developing anti-pegloticase antibodies. In these
phase III trials, the authors showed that the titre of anti-
pegloticase was important. Those who developed high
titre antibodies (>1:2430) almost invariably lost their
response to the drug, whereas 52/82 patients who had
lower titre anti-pegloticase retained their response.
Furthermore, a higher titre was associated with increased
risk of infusion reactions, which were reported in 31/52
patients with high titre anti-pegloticase and 16/84 with
low titre anti-pegloticase.
In summary, PEGylation has facilitated the development
of a new drug for patients with refractory gout. The rela-
tively low response rates in the phase III trials must be
viewed with the knowledge that these were patients who
were already very difficult to treat. PEGylation of uricase
did fulfil the aims of increasing the half-life and allowing
infrequent dosing—even monthly doses are appreciably
better than placebo—but there is a high frequency of anti-
bodies to pegloticase and higher antibody levels are
related to poorer clinical outcomes. However, the particu-
lar issue of s.c. injection site reactions that necessitated
i.v. use of this drug may be specific to pegloticase, as it is
thought to be related to localized release of hydrogen per-
oxide when urate is oxidized.
PEGylated therapies in RA
TNF-a inhibitors have been used as an alternative treat-
ment for patients with RA who fail to respond to standard
DMARDs. There are currently four non-PEGylated TNF in-
hibitors on the market, all of which have been shown to be
effective in patients with RA [19]. Certolizumab pegol
(CZP), the first PEGylated TNF inhibitor, has recently
been introduced into clinical practice. No head-to-head
trials of the five different anti-TNF agents have been car-
ried out, but meta-analyses suggest that all have similar
efficacy and safety characteristics [19, 20].
An early attempt to treat RA with PEGylated TNF recep-
tor utilized a conjugate [TNF binding protein (TNFbp)] in
which two molecules of the extracellular domain of TNF-RI
were conjugated with PEG [21]. Although this construct
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was effective at inhibiting the biologic effects of TNF, e.g.
in a murine model of multiple sclerosis [21], a phase I/II
clinical trial in patients with active RA was not successful
[22]. There were 33 patients in the study and doses
of TNFbp ranging from 30 to 100mg/kg were given intra-
venously at baseline, 3 and 6 weeks. Although there
was some reduction in the swollen and tender joint
counts at 21 days, the development of antibodies to the
drug occurred in 88% of subjects that received it.
Furthermore, the presence of these antibodies increased
clearance and reduced the half-life of the drug. These
effects were magnified after repeated doses, so this mol-
ecule was considered non-viable as a long-term treatment
for RA in the clinic [22]. After further studies to identify
soluble TNF-R-based drugs with better pharmacothera-
peutic properties than TNFbp (including low immuno-
genicity), a PEGylated monomeric form of sTNF-R1
(PEGsTNF-R1 or pegsunercept) was selected for further
evaluation.
PEGsTNF-R1 was initially designed as an anti-angio-
genic factor in RA [23]. It did reduce swelling and general
pain, showing a good effect [2325] when initially tested in
an RA model in rats, and showed good activity when used
as a monotherapy and in combination therapy with other
drugs such as dexamethasone and indomethacin [26]
or with IL-1 receptor antagonists; however, it showed
little effect on neovascularization in animal models and
induced an IgM response in several experiments
[2325]. Other studies in primates have shown no anti-
genic response in multiple or single dosing studies [26].
It is currently being taken forward to phase II clinical trials.
This drug remains a promising route of research, but it is
hard to judge the effect it will have in the clinic when it is
so early in the process of development. In contrast, CZP
has shown more long-term success and is already
licensed for the treatment of RA.
CZP is an Fc-free anti-TNF-a humanized Fab fragment
bound to 40 kDa PEG. PEGylation has increased its half-
life to 14 days [11, 20, 27]. The drug has gone through
several clinical trials [11, 20, 27, 28] that have shown
promising results for long-term care.
No preclinical data in animals have been published re-
garding this drug. One small-scale phase II study initially
showed both a low antibody response in humans when
the drug is given in high doses, extended half-life in com-
parison with most TNF-a inhibitors (14 days) and clinical
improvement that compared favourably with etanercept
and infliximab [29]. A number of phase III trials have
followed.
The RA Prevention of Structural Damage (RAPID) 1 [27]
and RAPID 2 [30] studies were both multi-centre, rando-
mized, double-blind, placebo-controlled trials that tested
the efficacy of CZP given in combination with MTX in
patients with RA not controlled by MTX alone. In the
RAPID 1 study there were three groups: 400 mg CZP
every 2 weeks (n= 390), 400 mg CZP at weeks 0, 2 and
4 followed by 200 mg CZP every 2 weeks (n= 393) and
placebo every 2 weeks (n= 199). Patients in all three
groups continued MTX at the same dose that they were
taking at study entry. The protocol for RAPID 2 was very
similar, although the trial was shorter (24 weeks) and smal-
ler (total number of subjects = 619).
There were clear differences between the CZP and pla-
cebo groups in both RAPID trials. For example, in RAPID 1
the percentage of patients completing 52 weeks treatment
was 70.3% in the 400 mg CZP group, 64.9% in the 200 mg
CZP group and 21.6% in the placebo group [27]. In fact,
62.8% of the placebo group had withdrawn due to lack of
efficacy by week 16. After just 1 week of treatment signifi-
cantly more patients in the treatment groups achieved
ACR20 responses than with placebo (22.9% for 200 mg,
22.3% for 400 mg and 5.6% for placebo) [27]. Differences
between the CZP and placebo groups remained signifi-
cant for the entire follow-up period [27]. ACR50 and
ACR70 responses were also better in the CZP group com-
pared with the placebo group. Secondary outcomes were
better in the treatment groups than in the placebo group
regarding the slowing of structural damage (using Sharp
radiological scores), improved physical function, quality of
life and general patient well-being [20, 27]. Most adverse
effects were mild or moderate and withdrawal due to ad-
verse events was rare—3.3, 5.6 and 7.0 per 100 patient-
years in the placebo, 200 and 400 mg groups, respectively
[27]. There were no drug-related deaths. Very similar re-
sults were seen in RAPID 2 [30], with the additional finding
from an open-label extension period that clinical and
radiological benefits were sustained for up to 3 years
and only two patients withdrew from CZP due to lack of
efficacy [30]. Antibodies to CZP were seen in 6.4% of
patients who received it in RAPID 1 and 5.1% in RAPID
2, which is in keeping with the naturally circulating anti-
PEG levels in the population [12]. The number of antibody-
positive patients was too low to detect any effect on
clinical response.
Evidence for efficacy of CZP given subcutaneously as
monotherapy comes from the Efficacy and Safety of
CZP—4 Weekly Dosage in RA (FAST4WARD) study, in
which patients who had failed one or more DMARDs
were randomized to either CZP 400 mg (n= 111) or pla-
cebo (n= 109) every 4 weeks for a period of 24 weeks. The
results showed better outcomes for patients on CZP as
opposed to the placebo group [11]. Significantly fewer
patients in the CZP group than the placebo group with-
drew due to lack of efficacy (21.6% vs 68.8%, P< 0.001).
At week 24, ACR20, 50 and 70 response rates were all
significantly better in the treatment group compared with
the placebo group—45.5% vs 9.3%, 22.7% vs 3.7% and
5.5% vs 0% for ACR20, 50 and 70, respectively. In the
treatment group, 8.1% were positive for anti-CZP antibo-
dies, which reduced the effect on ACR20 at week 24 by
5%—this is a common effect of neutralizing antibodies
in biologic therapeutics [3, 11, 20]. There were also
improvements in HAQ Disability Index (HAQ-DI) values,
pain and fatigue in the treatment groups [11]. Most
adverse effects were mild or moderate. There were no
deaths.
Further studies (reported in abstract form only) extend
the possible range of patients in whom CZP may be
effective. The RA Evaluation in Subjects Receiving TNF
Inhibitor CZP (REALISTIC) study [31] includes >1000
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subjects, of whom 38% had already received some form
of TNF inhibition therapy, i.e. this study looks at the po-
tential use of CZP in ‘anti-TNF failure’ patients. Subjects
were randomized to receive either CZP 200 mg fortnightly
or placebo. Whereas 216 subjects received CZP mono-
therapy, 635 received CZP with a DMARD and 212
received placebo (with or without a DMARD). At 12 weeks
the ACR20 response was achieved in 51% of CZP-treated
patients compared with 26% of placebo-treated patients.
Importantly, this level of response to CZP was achieved
regardless of whether patients were on DMARDs, which
DMARDs were given or whether they had previously failed
other TNF inhibition treatments. Preliminary results of the
CZP in the Treatment of RA Remission Induction and
Maintenance in Patients With Low Disease Activity
(CERTAIN) study [30] show that even patients with low
or moderate disease activity may benefit from CZP in
combination with DMARDs. Of 194 such patients
recruited and randomized to CZP (400 mg at weeks 0, 2
and 4 followed by 200 mg every fortnight) or placebo, only
37% of CZP patients had moderate or high activity at
24 weeks compared with 70% of the placebo group. At
both 20 and 24 weeks, more than twice as many patients
on CZP as on placebo were in remission from RA.
In summary, there is clear trial evidence that CZP is
effective in treating patients with DMARD-non-responsive
RA both as monotherapy and in combination and emer-
ging evidence for its use in patients with low to moderate
disease activity and those who have failed other TNF
inhibitors, although there is nothing to suggest that it is
more effective after one TNF failure than other anti-TNFs.
The efficacy and safety seen are comparable to those for
the other TNF-a inhibitors [20, 27]. A unique feature of
CZP is the lack of an Fc component (which also necessi-
tates the use of PEGylation or some other means of
increasing the size of the Fab), and some have argued
that this would be advantageous in preventing this drug
from crossing the placenta [20]. However, there are as yet
no convincing data to guide us in using any form of TNF
inhibition during pregnancy.
Conclusion
PEGylated biologics in rheumatology: the future or a
distraction
In the development of PEGylated uricase and CZP the
potential drawbacks of PEGylation (such as heterogen-
eity, reduced activity and immunogenicity) did not apply
or have been circumvented. Different PEGylated agents
produce different levels of antibody response. Most
patients treated with pegloticase develop anti-drug anti-
bodies (which can affect efficacy), whereas very few
patients treated with CZP develop anti-CZP antibodies.
PEGylation increased the half-life of both agents, allowing
fortnightly or monthly doses to be effective.
The nature of the molecule to be PEGylated is critically
important. In the case of pegloticase, a recombinant
artificial uricase with optimal properties was designed. In
the case of CZP, an Fc-free Fab was used. Pegloticase
has relatively poor efficacy data compared with CZP, but
may be used in patients for whom there is currently no
other effective drug. In contrast, CZP would have failed
had it not been as effective in trials as the other TNF in-
hibitors available. There is therefore reason to believe that
PEGylated drugs will find a role both for small groups of
refractory patients and in broadening the range of avail-
able agents for wider groups of patients.
In conclusion, successful trials of PEGylated agents in
gout and RA have shown that the potential gains from
PEGylation can be realized whereas the potential draw-
backs can be circumvented. PEGylation of relatively small
molecules (as in both these examples) may be especially
important in the future.
Rheumatology key messages
. PEGylation is a chemical method of modifying
biologic molecules to increase half-life in vivo,
enhancing their therapeutic utility.
. Potential disadvantages of PEGylation include
reduced activity and immunogenicity.
. CZP for RA and pegloticase for gout are in clinical
use after being tested in trials.
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